Tricida (TCDAQ) Versus Its Competitors Head to Head Comparison
Tricida (TCDAQ) Versus Its Competitors Head to Head Comparison
Tricida (NASDAQ:TCDAQ – Get Rating) is one of 986 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it weigh in compared to its competitors? We will compare Tricida to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, risk, earnings, profitability and dividends.
Tricida（纳斯达克股票代码：TCDAQ — Get Rating）是 “药物制剂” 行业986家上市公司之一，但与竞争对手相比，它的影响如何？我们将根据Tricida的估值实力、机构所有权、分析师建议、风险、收益、盈利能力和分红将Tricida与相关业务进行比较。
Profitability
盈利能力
This table compares Tricida and its competitors' net margins, return on equity and return on assets.
该表比较了Tricida及其竞争对手的净利润、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Tricida | N/A | N/A | -103.81% |
| Tricida Competitors | -3,401.47% | -345.78% | -38.40% |
| 净利润 | 股本回报率 | 资产回报率 | |
| Tricida | 不适用 | 不适用 | -103.81% |
| Tricida 竞争对手 | -3,401.47% | -345.78% | -38.40% |
Risk & Volatility
风险与波动性
Tricida has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Tricida's competitors have a beta of 0.93, indicating that their average stock price is 7% less volatile than the S&P 500.
Tricida的beta值为0.12，这表明其股价的波动性比标准普尔500指数低88％。相比之下，Tricida的竞争对手的beta值为0.93，这表明他们的平均股价波动性比标准普尔500指数低7％。
Insider and Institutional Ownership
内部所有权和机构所有权
40.6% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 35.6% of Tricida shares are owned by company insiders. Comparatively, 15.6% of shares of all "Pharmaceutical preparations" companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
所有 “药物制剂” 公司的40.6％的股份归机构投资者所有。35.6％的Tricida股份由公司内部人士拥有。相比之下，所有 “药物制剂” 公司的15.6％的股份由公司内部人士拥有。强大的机构所有权表明，大型基金经理、捐赠基金和对冲基金认为一家公司已为长期增长做好了准备。
Valuation and Earnings
估值和收益
This table compares Tricida and its competitors gross revenue, earnings per share (EPS) and valuation.
该表比较了Tricida及其竞争对手的总收入、每股收益（EPS）和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Tricida | N/A | -$176.57 million | 0.00 |
| Tricida Competitors | $8.39 billion | $241.80 million | -3.67 |
| 总收入 | 净收入 | 市盈率 | |
| Tricida | 不适用 | -1.7657 亿美元 | 0.00 |
| Tricida 竞争对手 | 83.9 亿美元 | 2.4180 亿美元 | -3.67 |
Tricida's competitors have higher revenue and earnings than Tricida. Tricida is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Tricida的竞争对手的收入和收益都高于Tricida。Tricida的市盈率高于竞争对手，这表明它目前比该行业的其他公司更昂贵。
Analyst Recommendations
分析师建议
This is a breakdown of current ratings and recommmendations for Tricida and its competitors, as reported by MarketBeat.
据MarketBeat报道，这是Tricida及其竞争对手当前评级和推荐的明细。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tricida | 0 | 0 | 0 | 0 | N/A |
| Tricida Competitors | 4157 | 15005 | 41469 | 711 | 2.63 |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| Tricida | 0 | 0 | 0 | 0 | 不适用 |
| Tricida 竞争对手 | 4157 | 15005 | 41469 | 711 | 2.63 |
As a group, "Pharmaceutical preparations" companies have a potential upside of 118.01%. Given Tricida's competitors higher possible upside, analysts clearly believe Tricida has less favorable growth aspects than its competitors.
作为一个整体，“药物制剂” 公司的潜在上涨空间为118.01％。鉴于Tricida的竞争对手可能更高的上行空间，分析师显然认为Tricida的增长方面不如竞争对手那么有利。
Summary
摘要
Tricida competitors beat Tricida on 6 of the 10 factors compared.
在比较的10个因素中，Tricida的竞争对手在6个因素上击败了Tricida。
Tricida Company Profile
Tricida 公司简介
(Get Rating)
（获取评分）
Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.
Tricida, Inc. 是一家制药公司。它专注于其产品 TRC101 的开发和商业化，这是一种非吸收、口服给药的聚合物药物，旨在治疗慢性肾脏病患者的代谢性酸中毒。该公司由格里特·克拉尔纳和克雷格·乔恩·霍克于2013年5月22日创立，总部位于加利福尼亚州南旧金山。
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Tricida Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Tricida及相关公司的最新新闻和分析师评级的简明每日摘要。